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Abstract The present study was aimed at investigating effects
of hypochlorite (HOCl) modification of high density lipoproteins
subclass 3 (HDL3) on their ability for cellular cholesterol
removal from permanent J774 macrophages. Our findings
indicate that HOCl (added as reagent or generated enzymati-
cally by the myeloperoxidase/H2O2/Cl3 system) damages
apolipoprotein A-I, the major protein component of HDL3.
Fatty acid analysis of native and HOCl-modified HDL3 revealed
that unsaturated fatty acids in both major lipid subclasses
(phospholipids and cholesteryl esters) are targets for HOCl
attack. HOCl modification resulted in impaired HDL3-mediated
cholesterol efflux from J774 cells, regardless of whether reagent
or enzymatically generated HOCl was used to modify the
lipoprotein. Decreased cholesterol efflux was also observed after
HOCl modification of reconstituted HDL particles. Impairment
of cholesterol efflux from macrophages was noticed at low and
physiologically occurring HOCl concentrations.
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1. Introduction
In contrast to low density lipoproteins (LDL), high plasma
concentrations of high density lipoproteins (HDL) are associ-
ated with a decreased risk for the development of coronary
artery disease, an e¡ect commonly attributed to their central
role in reverse cholesterol transport [1]. During this process
HDL promotes cholesterol e¥ux from peripheral tissues and
the accepted cholesterol is partially re-esteri¢ed by the action
of lecithin-cholesterol acyltransferase (LCAT) [2]. Cholesteryl
esters (CEs) formed by the LCAT reaction are then trans-
ferred from HDL to other lipoproteins by the cholesterol ester
transfer protein (CETP) or are delivered to the liver for biliary
secretion or reutilization during lipoprotein assembling [3].
Hepatic (selective) uptake of HDL-associated CEs is mediated
via scavenger receptor BI (SR-BI) in rodents [4]. SR-BI par-
ticipates in cellular lipid/cholesterol e¥ux [5] and phospho-
lipids may have a major role in mediating this process [6].
However, not only phospholipids, but also apolipoprotein
A-I (apoA-I) plays a crucial role during removal of cellular
cholesterol [7,8] and some distinct regions within apoA-I are
involved this process [9^13]. Oxidation/modi¢cation of HDL
was demonstrated to result in diminished cholesterol e¥ux,
¢ndings attributed to alterations of the apoprotein domain
[14^16]. Within these modi¢cations oxidative tyrosylation ap-
pears to be an exception since tyrosyl radical modi¢cation of
HDL enhanced cellular cholesterol e¥ux and mobilization
[17,18].
Among the numerous in vitro oxidation systems the mye-
loperoxidase (MPO)/H2O2/halide system has emerged as an
oxidant being of potential in vivo relevance. Hypochlorite
(OCl3), formed in vivo via the MPO/H2O2/Cl3 system from
activated neutrophils and/or monocytes, may react with a
wide range of biological target molecules, including lipids,
antioxidants and proteins [19]. The importance of MPO as a
potential in vivo oxidant is further underlined by the presence
of enzymatically active MPO in human atherosclerotic lesions
[20], the presence of HOCl-modi¢ed (lipo)proteins in ad-
vanced human atherosclerotic lesions [21] and in£ammatory
kidney tissues rich in MPO [22]. In vitro, the MPO/H2O2/
halide system transforms LDL [23] and HDL [24] into high
uptake forms for macrophages and it was shown that HDL3
modi¢ed by polymorphonuclear cells (containing high concen-
trations of MPO) had a markedly reduced ability to remove
cholesterol from cells [25].
Therefore, the present study was aimed at investigating the
consequences of HOCl added as reagent or generated by the
MPO/H2O2/halide system on HDL3-mediated cholesterol ef-
£ux from J774 macrophages. In order to di¡erentiate between
e¡ects mediated by modi¢ed lipids and/or apoprotein modi¢-
cation we used human HDL3 and reconstituted HDL particles
(rHDL), the latter composed of saturated fatty acids which
are not susceptible to OCl3 modi¢cation.
2. Materials and methods
2.1. Preparation of human, apo E-free HDL3
Human apo E-free HDL3 was prepared by density gradient ultra-
centrifugation of plasma obtained from human normolipidemic vol-
unteers in a TL120 Beckman tabletop ultracentrifuge (Beckman, Aus-
tria) as described [26]. SDS-PAGE on 15% gels and subsequent
Coomassie staining revealed the presence of apoA-I as the major
apolipoprotein.
2.2. Isolation of apoA-I
HDL was isolated from plasma obtained from human normolipi-
demic volunteers by sequential ultracentrifugation and delipidated as
described [27]. The delipidated apoproteins were redissolved in 50 mM
glycine, 4 mM NaOH, 0.5 M NaCl and 6 M urea (pH 8.8). HDL
apoproteins were then separated by size exclusion chromatography on
a Sephacryl S-200 column (3U150 cm) as described [27]. The fractions
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containing the major peak were pooled and dialyzed against
NH4HCO3. The product was homogeneous as assessed by SDS-
PAGE, reversed phase HPLC and amino acid analysis.
2.3. Preparation of rHDL
rHDL was prepared by the sodium cholate dialysis method using
dipalmitoyl phosphatidylcholine (DPPC), apoA-I and Na-cholate in
molar ratios of 120:1:100 as described [28]. Brie£y, 14.2 mg DPPC
was dissolved in 1 ml bu¡er (10 mM Tris, pH 8.0, 0.15 M NaCl,
0.005% EDTA and 1 mM NaN3) containing 6.2 mg Na-cholate.
The mixture was stirred at 40‡C for 90 min. After the addition of
apoA-I (4 mg/1.4 ml) and stirring at 40‡C (20 min) the mixture was
incubated at 37‡C for 16 h. Dialysis with exhaustive bu¡er changes
was performed at 20‡C over 3 days. Samples were kept under N2 and
protected from light. rHDL was reisolated by gradient ultracentrifu-
gation using a TLA 100.4 rotor (Beckman, Austria) as described [26].
The chemical composition of rHDL was obtained by protein deter-
mination using the Lowry procedure [29], the phospholipid (PL) con-
tent was measured enzymatically (BioMerieux, France). The content
of apoA-I molecules/rHDL was obtained by dimethylsuberimidate
(DMS) crosslinking as described by Swaney [30].
2.4. NaOCl modi¢cation of apoA-I
One mg apoA-I/ml PBS (10 mM, pH 6) was incubated with NaOCl
(Sigma, Austria) solution at the indicated molar ratio of NaOCl:
apoA-I as described earlier [24]. The concentration of NaOCl was
determined using a molar absorption coe⁄cient for NaOCl of
350 cm31 at 292 nm. NaOCl was added once, the mixture gently
vortexed, then kept on ice for 30 min and 90 min at 37‡C. Modi¢ed
apoA-I was dialyzed against water at 4‡C.
2.5. MPO modi¢cation of apoA-I
To 1 mg apoA-I/ml PBS (50 mM, pH 7.4) 15 additions of 20 WM
H2O2 were made at 10 min intervals at 37‡C [24]. 13 nM MPO (25 U/
ml; Alexis Co., Switzerland) was added at the start and subsequently
at every second addition of H2O2. At alternate additions of H2O2,
2 WM ascorbate was added. The reaction mixture was incubated for
1 h at 37‡C and dialyzed against water at 4‡C.
2.6. SDS-PAGE and Western blotting
ApoA-I samples were run for 90 min at 150 V in a Bio-Rad mini-
protean chamber (Bio-Rad, Austria). Proteins were electrophoretically
transferred to nitrocellulose membranes (150 mA, 4‡C, 90 min). For
the detection of native apoA-I a polyclonal rabbit anti-human apoA-I
antibody was used [24], followed by a HRP-conjugated goat anti-
rabbit IgG (Sigma, Austria). Immunochemical detection of NaOCl-
modi¢ed apolipoproteins was performed with a monoclonal antibody
2D10G9 [31] followed by peroxidase-conjugated goat anti-mouse IgG
(Sigma). Detection was performed by the ECL method (Amersham,
Austria). Amino acid analysis of native and NaOCl-modi¢ed HDL3
was performed as described previously on 6 N HCl hydrolysates (24 h,
105‡C) [24].
2.7. Fatty acid analysis of lipid subclasses and total HDL3 lipids
FA analysis of total HDL3 lipids and HDL3 lipid subclasses was
performed as described [32]. Brie£y, total HDL3 lipids were converted
to the corresponding FA methyl esters (FAMEs) in toluene (0.5 ml)
and methanol/BF3 complex (Sigma; 20%, v/v; 1 ml) with heptadeca-
noic acid as the internal standard (100 Wg). The FA composition of
the PL and CE fractions was analyzed after in situ transesteri¢cation
of the corresponding TLC spots exactly as described [32]. Separation
was performed on a FFAP-CB column (25 m, 0.35 mm i.d. ; Chrom-
pack, Austria) using a HP 5890 gas chromatograph equipped with a
£ame ionization detector and a split/splitless injector (Hewlett-Pack-
ard Co., Austria). After an initial isothermal period of 5 min at 150‡C
the temperature was programmed to 190‡C at 4‡/min and then to
215‡C at 2‡/min, with a hold at 215‡C for 15 min. Concentrations
of the individual FAs were calculated by peak area comparison with
the internal standard.
2.8. Cholesterol e¥ux studies
J774 mouse macrophages (ATCC, Rockville, MD, USA) were
plated on 6 well trays in RPMI 1640 medium containing 10% (v/v)
fetal calf serum (FCS) as described [33]. One day prior to the experi-
ments at approximately 80% con£uence the cells were preincubated in
RPMI 1640 containing lipoprotein-depleted serum (LPDS, 10%, v/v)
and the indicated activities of [3H]cholesterol (added as an ethanolic
solution; ¢nal volume 6 0.1% of total volume) as described [34]. This
procedure was shown to result in predominant labeling of the plasma
membrane-located cholesterol pool. Before initiating the e¥ux experi-
ments the [3H]cholesterol-containing medium was aspirated then the
cells were washed twice in TBS (containing 5% (w/v) BSA) and twice
in TBS. E¥ux experiments were then initiated by the addition of
RPMI 1640 containing LPDS (10%, v/v) and native and modi¢ed
HDL3 or rHDL at the concentrations indicated. At the indicated
time points the medium was collected and counted on a L-counter
(Packard-Canberra, Austria). The cells were lysed in 0.3 N NaOH
to determine the cellular protein content [29]. E¥ux of radioactive
label to the medium was calculated as the percentage of radioactivity
present in the cells prior to the addition of the indicated cholesterol
acceptors.
3. Results
The FA composition of total HDL3 lipids and the FAs
contained in the PL and CE fractions of HDL3 is shown in
Table 1. The PL fraction contains about one third more un-
saturated FAs as compared to the CE fraction (306 vs. 212
nmol/mg HDL3). With respect to FA composition of the two
lipid subclasses, unsaturated FAs constitute 85% of the CE
and 47% of the PL fraction (Table 1).
It is well established that during HDL3-mediated cholester-
ol e¥ux PLs have an important contribution to the particle’s
e¥ux abilities [35,36]. To identify whether one of the major
HDL3 lipid subclasses represents a preferred target for NaOCl
attack, HDL3 was modi¢ed with increasing molar ratios of
NaOCl, the lipids were extracted, separated by TLC, trans-
methylated and analyzed by gas chromatography (GC) as
described in Section 2. Modi¢cation of HDL3 with
NaOCl:HDL3 molar ratio v 100:1 led to pronounced con-
sumption of FAs in the PL (Fig. 1A) and CE fractions (Fig.
1B). At all NaOCl ratios studied, the degree of FA consump-
tion was related to the degree of unsaturation, i.e. modi¢ca-
tion occurred in the order C22:6s 20:4s 18:3s 18:2s 18:1.
For more clarity only FAs contributing v 6% of the total FA
content are shown. From the data shown in Fig. 1 it appears
that PL-located FAs are slightly more sensitive to HOCl dam-
age as compared to polyunsaturated FAs in the CE fraction.
The e¡ects of reagent and enzymatically generated OCl3 on
Table 1
Fatty acid composition of HDL3 phospholipids, cholesteryl esters
and total HDL3 lipids
Fatty acids nmol/mg total HDL3 mass
Total lipids Phospholipids Cholesteryl esters
14:0 12.1 þ 0.5 9.2 þ 1.1 1.2 þ 1.6
16:0 307.8 þ 9.8 234.1 þ 7.6 33.9 þ 4.1
16:1 28.4 þ 1.4 16.5 þ 4.2 1.1 þ 0.9
18:0 102.6 þ 5.4 99.7 þ 2.7 2.9 þ 0.8
18:1 (n-9) 201.9 þ 4.2 115.1 þ 5.9 67.3 þ 3.1
18:1 (n-7) 12.0 þ 1.1 n.d. 6.4 þ 4.6
18:2 264.0 þ 13.5 140.0 þ 3.5 105.6 þ 4.7
18:3 1.1 þ 0.9 1.5 þ 0.7 n.d.
20:4 59.8 þ 3.7 31.0 þ 4.9 29.9 þ 2.1
22:6 7.2 þ 2.6 4.7 þ 2.5 1.2 þ 0.2
TOTAL 996.9 þ 43.1 651.8 249.5
Total HDL3 lipids were either directly transmethylated with metha-
nol-containing BF3 (20%) or preseparated by TLC to analyze the
FAs present in the PL and CE fractions. The FA content was quan-
titated by peak area comparison with heptadecanoic acid used as in-
ternal standard. Results shown represent mean þ S.D. from triplicate
analyses and are given in nmol FA/mg total HDL3 mass.
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the apoprotein domain of HDL3 is shown in Fig. 2. HDL3 or
rHDL was modi¢ed in the presence of a 100-fold molar excess
of NaOCl or in the presence of the MPO/H2O2/Cl3 system.
The apoproteins were separated by SDS-PAGE (5^25% gels),
transferred to nitrocellulose and analyzed by immunoblotting
using either a rabbit human anti-apoA-I antiserum or a
monoclonal antibody (clone 2D10G9) speci¢cally recognizing
HOCl-modi¢ed epitopes. ApoA-I in native HDL3 or rHDL
was detected as a single, homogeneous band with an apparent
molecular mass of 28 kDa (lanes 1 and 5) and was free of any
preformed epitopes recognized by 2D10G9 (lanes 2 and 6).
However, NaOCl modi¢cation of HDL3 and rHDL resulted
in extensive apoprotein modi¢cation and generation of high
molecular weight apoA-I aggregates readily recognized by
2D10G9 (lanes 3 and 7). Most importantly enzymatic mod-
i¢cation with the MPO/H2O2/Cl3 system resulted in similar
OCl3-modi¢ed apoA-I aggregates in HDL3 (lane 4) and
rHDL (lane 8). To identify preferential amino acid targets,
the amino acid composition of native and NaOCl-modi¢ed
(25- and 100-fold molar excess) apoA-I was analyzed. From
the data shown in Table 2 it is evident that methionine resi-
dues are early targets and are destroyed at low oxidant:pro-
tein ratios (25:1). At a molar oxidant:apoA-I ratio of 100:1
Lys and Arg were partially (16 and 75%, respectively) modi-
¢ed, while Tyr, Phe, and His were quantitatively lost.
Next we have investigated the e¡ect of increasing NaOCl
modi¢cation on the ability of HDL3 to promote cellular chol-
esterol e¥ux from J774 macrophages. It is evident that at all
time points analyzed (3, 6 and 24 h; Fig. 3A) the degree of
cholesterol e¥ux was dependent on the degree of HDL3 mod-
i¢cation (ranging from 25 to 800:1). The cholesterol acceptor
properties of HDL3 modi¢ed with a v100-fold molar excess
of NaOCl were signi¢cantly lower than observed with native
HDL3 and HDL3 modi¢ed with lower NaOCl ratios. The
percentage of cholesterol e¥ux to the acceptors was depend-
ent on the modi¢cation rate and decreased from 29 þ 0.3 to
11 þ 1.1 (3 h), 38 þ 0.5 to 20 þ 0.9 (6 h) and 62 þ 2.9 to
40 þ 0.5% (24 h) (native vs. HDL3 modi¢ed at a molar ratio
of 400:1). Modi¢cation of HDL3 with an 800-fold molar ex-
cess of NaOCl led to only a small further decrease in choles-
Fig. 2. Western blot of native, NaOCl- and MPO-modi¢ed HDL3
and rHDL. Prior to SDS-PAGE, HDL3 or rHDL was modi¢ed
with NaOCl (100-fold molar excess) or in the presence of the MPO/
H2O2/Cl3 system. Samples containing 100 ng apoA-I were separated
on 5^25% gels and transferred to nitrocellulose. Native apoA-I of
HDL3 (lane 1) or rHDL (lane 5) was detected with rabbit anti-hu-
man apoA-I antiserum and was undetectable with monoclonal
2D10G9 (lanes 2 and 9, respectively). NaOCl- and MPO-modi¢ed
apoA-I of HDL3 (lanes 3 and 4) or the corresponding rHDL sam-
ples (lanes 7 and 8) were detected with monoclonal antibody, clone
2D10G9 speci¢cally recognizing OCl3-modi¢ed epitopes. Visualiza-
tion was performed with peroxidase-conjugated goat anti-rabbit or
goat anti-mouse IgG using the ECL method. The molecular mass of
the marker proteins is indicated.
Fig. 1. FA composition of HDL3 phospholipids (A) and cholesteryl
esters (B) prior to and after NaOCl modi¢cation. HDL3 (1 mg/ml)
was modi¢ed in the presence of the indicated molar excess of
NaOCl as described in Section 2. After modi¢cation the lipids were
extracted and the main lipid subclasses were separated on silica gel
60 plates. The bands corresponding to the PL and CE fractions
were scraped o¡ the plate and analyzed as described in Section 2.
Results shown are mean values from two independent experiments.
The absolute FA concentrations of the corresponding fraction in na-
tive HDL3 are shown in Table 1.
Table 2
Amino acid analysis of NaOCl-modi¢ed apoA-I
Amino acida NaOCl:apoA-I (mol/mol)
0 25 100
Met 2 n.d. n.d.
Tyr 6 6 n.d.
Phe 6 5 n.d.
Lys 19 18 16
His 6 6 n.d.
Arg 12 11 3
Native apoA-I (500 Wg) in PBS (1 ml) was modi¢ed with NaOCl
(25- and 100-fold oxidant excess). Amino acid analysis was per-
formed on hydrolysates prepared with 6 N HCl (105‡C, 24 h).
n.d. = not detectable.
aValues are given in mol amino acid/mol apoA-I and represent
mean values from two independent experiments. Only amino acids
which are modi¢ed by NaOCl treatment are shown.
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terol e¥ux. From the data shown in Fig. 3 we have calculated
(by non-linear regression analysis) the time necessary to me-
diate 50% cholesterol e¥ux (d/2). The d/2 values for native
and the various HDL3 modi¢cations are summarized in Table
3. These calculated values show that the time necessary to
remove half of [3H]cholesterol progressively increased from
V15 h (native) to v 30 h with increasing modi¢cation rates.
To compare the e¡ects of reagent OCl3 and enzymatically
generated OCl3 on cholesterol e¥ux properties of HDL3 ef-
£ux experiments were performed in a time- (Fig. 3B) and
concentration-dependent (Fig. 3C) manner and were con-
ducted for shorter incubation times (90^150 min). With native
HDL3 cholesterol e¥ux occurred in a nearly linear manner
and resulted in a removal of V6% of the initially cell-associ-
ated radioactivity per hour (Fig. 3B). The corresponding val-
ues for NaOCl- and MPO-modi¢ed HDL3 were 3.6 and 4.8%/
h. From the data shown in Fig. 3B it is evident that HDL3
modi¢cation with either reagent or the MPO/H2O2/Cl3 sys-
tem resulted in a comparable impairment in cholesterol ac-
ceptor properties. This was also obvious in concentration-de-
pendent experiments where cholesterol e¥ux mediated by
NaOCl- and MPO-modi¢ed HDL3 was 10^30% lower than
observed in the presence of native HDL3 (Fig. 3C).
Modi¢cation of HDL3 with NaOCl results in alterations of
the apoprotein and the lipid domain (Figs. 1 and 2). To be
able to di¡erentiate between e¡ects of lipid and apoprotein
modi¢cations on cholesterol acceptor properties of HDL3 we
prepared rHDL particles with DPPC as the PL species. As
Fig. 3. NaOCl or MPO modi¢cation of HDL3 or rHDL results in decreased cellular cholesterol e¥ux. J774 macrophages were cultivated in
RPMI 1640 medium until V80% con£uence as described in Section 2. The cells were labeled in the presence of [3H]cholesterol (0.1 or 1 WCi/
well/ml; 24 h) and washed as described in Section 2. A: 500 Wg of native or modi¢ed HDL3 (molar NaOCl:apoA-I ratio = 25:1^800:1) was
added to the cells in RPMI 1640 medium. The medium was removed at 3, 6 and 24 h to determine the radioactivity. At time zero the cells ac-
quired 9918 þ 911 cpm/well (n = 6). B: Cells were labeled with [3H]cholesterol (1 WCi/well), washed and received fresh medium containing 225
Wg of native, NaOCl- (200:1) or MPO-modi¢ed HDL3 protein. At the indicated time the medium was removed to determine the radioactivity.
At time zero the cells acquired 131 807 þ 9711 cpm/well (n = 3). C: Cells were labeled with [3H]cholesterol (1 WCi/well), washed and received the
indicated concentrations of native, NaOCl- (200:1) or MPO-modi¢ed HDL3 protein in fresh medium. After 90 min the medium was removed
to determine the radioactivity. At time zero the cells acquired 131 807 þ 9711 cpm/well (n = 3). D: Cells were labeled with [3H]cholesterol (1
WCi/well) and received the indicated concentrations of native and rHDL (containing 100 Wg apoA-I) modi¢ed with a 5^200-fold NaOCl excess.
After an incubation period of 240 min the medium was removed to determine the radioactivity. At time zero the cells have acquired
267 668 þ 16 232 cpm/well. Cellular cholesterol e¥ux is expressed as percentage medium radioactivity in terms of the radioactivity present in the
cells prior to the addition of the indicated acceptor particles (A^D). All results shown represent mean þ S.D. of triplicate dishes.
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can be seen from Fig. 1A, palmitic acid in the PL fraction is
not a¡ected by OCl3 treatment even at the highest
OCl3 :apoA-I molar ratios used (400:1). The rHDL prepara-
tion reisolated by ultracentrifugation contained three rHDL
species with Stokes radii of 18, 15 and 11 nm (as analyzed by
non-denaturing gradient gel electrophoresis) with the 11 nm
population contributing about 70%. The stoichiometry of
apoA-I in rHDL was determined by chemical crosslinking
using DMS [30]. In line with other reports we have observed
the presence of 2, 3 and 4 apoA-I molecules per rHDL par-
ticle [37]. The di¡erent rHDL subpopulations were not further
separated prior to the e¥ux experiments. rHDL was modi¢ed
with an increasing molar excess of NaOCl (5^200 mol/mol
apoA-I) and used as cholesterol acceptor vesicles during e¥ux
experiments. J774 cells were labeled with 1 WCi [3H]cholesterol
and acquired 267 668 þ 16 232 cpm/well, corresponding to ap-
proximately 25% of the initially added radioactivity. Cells
were then washed and incubated in the presence of 100 Wg
rHDL protein. When rHDL was modi¢ed at increasing NaO-
Cl:apoA-I molar ratios the e⁄cacy to promote cholesterol
e¥ux from J774 macrophages was signi¢cantly diminished
(Fig. 3D). The radioactivity recovered in the medium gradu-
ally decreased with increasingly modi¢ed rHDL preparations
(26 260 þ 624 cpm, native rHDL vs. 18 327 þ 296 cpm for
rHDL modi¢ed at 200:1). Most importantly, a small but sig-
ni¢cant decrease in cholesterol e¥ux became apparent at the
lowest modi¢cation (5:1).
4. Discussion
The functional integrity of apoA-I and the PL composition
of HDL are important determinants a¡ecting the particle’s
capability to promote cellular cholesterol e¥ux [6^8,38]. In
the present study we have observed impaired cholesterol e¥ux
from J774 macrophages to (reagent or enzymatically gener-
ated) OCl3-modi¢ed HDL. NaOCl modi¢cation of HDL3
resulted in the dose-dependent loss of unsaturated FAs in
the two major HDL lipid subclasses (PLs and CEs), a fact
most probably related to FA chlorohydrin formation
[24,39,40]. From the data shown in Fig. 1 it appears that
polyunsaturated fatty acids (PUFAs) present in the outer
PL shell are slightly more susceptible to OCl3 modi¢cation
than PUFAs located in the hydrophobic CE core, in line with
earlier observations during copper-mediated oxidation of
HDL [32]. It is well documented that the quantitative PL
content of HDL [35,36] as well as the PL subspecies compo-
sition of rHDL [41] modulate the e⁄cacy for cellular choles-
terol removal of a given acceptor particle. At present we have
no reasonable explanation inasmuch chlorohydrin formation
in the PL moiety contributes to the observed impairment in
cellular cholesterol e¥ux by NaOCl-modi¢ed HDL3. We
have, however, obtained two lines of evidence that apoprotein
(rather than PL) modi¢cations are responsible for decreased
cholesterol e¥ux to OCl3-modi¢ed acceptor particles: (i)
MPO modi¢cation does not a¡ect the lipid moiety of HDL3
[24] yet results in a comparable decrease of cholesterol e¥ux
as compared to NaOCl-modi¢ed HDL3 (Fig. 3B,C) and (ii)
NaOCl modi¢cation of discoidal apoA-I/dipalmitoyl phos-
phatidylcholine particles results in diminished cholesterol re-
moval (Fig. 3D) although palmitic acid is not modi¢ed by
NaOCl (Fig. 1).
In contrast to the lipid domain (see above), the apoprotein
domain of HDL undergoes comparable changes upon modi-
¢cation with either reagent or enzymatically generated HOCl
(Fig. 2). One of the amino acids present in apoA-I that are
highly sensitive to chemical and/or enzymatic oxidation is
methionine. Methionine oxidation of human apoA-I was ob-
served in vitro and in vivo [42,43]. ApoA-I can directly reduce
lipid hydroperoxides in vitro, a redox process accompanied by
oxidation of Met112 and Met148 to the corresponding methio-
nine sulfoxides [44,45]. Whether this reaction also occurs in
vivo (resulting in the formation of oxidized apoA-I in the
circulation) awaits clari¢cation. H2O2 oxidation of Met112
and Met148 in apoA-I resulted in a 30% impairment of chol-
esterol e¥ux capacity from human skin ¢broblasts as com-
pared to HDL containing unoxidized apoA-I [46]. In line with
these ¢ndings we have observed Met modi¢cation at low mo-
lar oxidant:apoA-I ratios (25:1; Table 2) and found a small
but signi¢cant reduction in cellular cholesterol e¥ux to rHDL
modi¢ed with a 5-fold OCl3 excess (Fig. 3D). Whether the
cholesterol acceptor properties of methionine sulfoxides con-
taining apoA-I could be restored by treatment with peptide
methionine sulfoxide reductase as suggested recently [47] re-
mains to be elucidated.
In addition to methionine residues, other amino acids lo-
cated in distinct regions of the apoA-I molecule are also of
importance for HDL-mediated cellular cholesterol removal.
The formation of aggregated apoA-I could be a result of
either inter- or intra-particle crosslinks via chloramine and
subsequent Schi¡ base [48] or dityrosine formation [49], a¡ect-
ing amino acids contributing to the functional properties of
HDL. Banka and colleagues [9] have identi¢ed two distinct
regions within apoA-I (amino acids 74^105 and 96^111) ap-
parently involved in cholesterol e¥ux from monocytes to
apoA-I proteoliposomes. Inhibition experiments with mono-
clonal antibodies directed against continuous epitopes of
apoA-I have revealed that regions within, or adjacent to, res-
idues 149^186 [10] and 140^150 [11] determine the ability of
apoA-I to promote cellular cholesterol e¥ux. Another amino
acid stretch important for cellular cholesterol removal was
identi¢ed in pre-L-HDL [13]. All of these epitopes which are
involved in the mobilization of cellular cholesterol contain
amino acids that are susceptible to NaOCl modi¢cation (Ta-
ble 2). We are currently attempting to identify distinct regions
in the apoA-I molecule that are a¡ected by HOCl treatment
and could be linked to impaired cholesterol e¥ux abilities of
apoA-I. Whether the structural integrity of the above men-
tioned apoA-I sequences is a requirement for SR-BI-depend-
ent cholesterol e¥ux [5,6] is at present not clear. However,
regardless of the precise mechanisms it is noteworthy that
Table 3
Calculated d /2 values
NaOCl:HDL3 (mol/mol) d /2 (h)
0 15 þ 0.9
5 9 þ 1.2
10 13 þ 0.8
50 14 þ 1.3
100 21 þ 0.8
200 32 þ 1.2
400 34 þ 1.1
800 35 þ 0.7
Data shown in Fig. 3A were subjected to non-linear regression anal-
ysis to calculate the times necessary to remove half of cell-associated
[3H]cholesterol (d /2).
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modi¢cation at low and physiologically occurring HOCl:
apoA-I molar ratios (5:1^50:1) during the present study led
to impaired cholesterol acceptor properties of rHDL. The
HOCl concentrations at sites of acute in£ammation were cal-
culated to be about 340 WM [50] and HDL3 plasma concen-
trations are between 6 and 12 WM, resulting in an approxi-
mate HOCl:apo A:I molar ratio of 30:1 to 50:1, supporting
the in vivo relevance of our study.
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